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Background: Many cancer cells develop resistance to tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis, necessitating combination with chemotherapy, and normal cells manifest side effects
due to the combined treatment regimen of TRAIL and chemotherapeutic drugs. A novel cancer therapy utilizing
TRAIL is thus urgently needed.
Results: In this study, we exploited TRAIL receptor-mediated endocytosis for the first time to produce a cell-
permeable molecule, soluble forms of recombinant TRAIL:iron superoxide dismutase (sTRAIL:FeSOD), which
possesses sTRAIL-induced apoptotic ability and FeSOD antioxidant activity. The FeSOD component was rapidly
introduced into the cell by sTRAIL and intracellular superoxide radical (O2
-), which have been implicated as
potential modulators of apoptosis in cancer cells, was eliminated, resulting in a highly reduced cellular
environment. The decrease in cellular O2
-, which was accompanied by a brief accumulation of H2O2 and
downregulation of phosphorylated Akt (p-Akt) and cellular FLICE-inhibitory protein, sensitized K562 leukemia cells
and human promyelocytic leukemia (HL-60) cells to TRAIL-induced apoptosis. The low H2O2 levels protected
human LO2 hepatocytes from sTRAIL:FeSOD-induced apoptosis despite downregulation of p-Akt. We also obtained
evidence that the lack of response to sTRAIL:FeSOD in normal T cells occurred because sTRAIL:FeSOD shows much
stronger shifts of redox state in erythroleukemia (K562) and HL-60 cells compared to that in normal T cells. K562
and HL-60 cells underwent sTRAIL:FeSOD-induced apoptosis without the dysfunction of mitochondria.
Conclusions: The fusion protein overcomes the inability of FeSOD to permeate the cell membrane, exhibits
synergistic apoptotic effects on K562 and HL-60 cells and demonstrates minimal toxicity to normal T cells and the
normal liver cell line LO2, indicating its potential value for the treatment of leukemia.
Background
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a potent anticancer therapeutic agent that
induces apoptotic cell death in cancer cells [1], regard-
less of P53 status. TRAIL is therefore a promising can-
cer therapeutic agent, especially for chemotherapy- or
radiotherapy-resistant cancer cells [2]. Preclinical studies
in mice and nonhuman primates with soluble forms of
recombinant TRAIL (sTRAIL) have shown strong tumor-
icidal activity in xenografted tumor models without
apparent toxic side effects [3,4]. However, certain TRAIL
preparations have been shown to be toxic to human
hepatocytes and keratinocytes, which may be responsible
for the considerable hepatotoxicity or fulminant hepatic
failure observed in human trials [5,6]. In addition, TRAIL
resistance has been observed in many cancer cells [7-9].
Thus, understanding the exact molecular determinants of
TRAIL resistance and developing strategies to overcome
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important prerequisites for the successful deployment of
TRAIL as a therapeutic agent.
Several different kinds of chemotherapy drugs are
used in combination with TRAIL to sensitize TRAIL-
resistant cancer cells, and many reports have combined
recombinant TRAIL with standard anticancer therapies
to induce synergistic tumor cell apoptosis [10,11]. How-
ever, there is evidence that some normal human cells
are sensitive to apoptosis after treatment by TRAIL in
combination with chemotherapeutic drugs [12,13].
Furthermore, mutation or deletion of p53 occurs in
more than half of all human tumors, and Akt is fre-
quently hyperactive in cancer cells. Both of these altera-
tions play a prominent role in cell resistance to
chemoradiotherapy. Edwin et al. [14] reported a recom-
binant fusion protein, single-chain variable fragment 425
(scFv425):sTRAIL, that combined the tumoricidal effect
of epidermal growth factor receptor signal inhibition
with target cell-restricted apoptosis induction, hence
showing promising antitumor activity. Thus, in recent
years, biological mechanism-based cancer therapeutic
strategies that may exert enhanced antitumor activity
and high tumor specificity have attracted much more
attention because of the unfavorable side effects of che-
moradiotherapy and the resistance of many tumor cells
to chemo- or radiotherapy [2,15].
Antioxidants have long been used for the treatment of
cancer, especially in combination with other anticancer
d r u g s[ 1 6 ] .S u p e r o x i d ed i s m u t a s e( S O D )i sat y p eo f
potent antioxidant enzyme that suppresses the growth
of various cancer cells by removing superoxide radicals
(O2
-) [17], which are critical in different stages of carci-
nogenesis. However, owing to its large molecular weight,
SOD cannot enter the cell to exert its effects. To over-
come this deficiency, a liposome can be used to enclose
SOD, allowing it to enter cells [18]. Additionally, we
have previously shown that a fusion of SOD with scFv
was able to permeate the cell membrane via receptor-
mediated endocytosis and was able to then inhibit cell
proliferation through the Akt/p27
kip1 pathway [19].
However, neither of these approaches effectively inhibits
cancer cell proliferation, and therefore engineering SOD
to permeate the cell membrane and exercise its powerful
cytotoxic effects is key to its clinical application.
Akt regulates the transactivation of antiapoptotic
molecules such as cellular FLICE-inhibitory protein (c-
FLIPL), X-linked inhibitor of apoptosis protein and the
antiapoptotic protein B-cell lymphoma-extra large (Bcl-
xL) [20-22]. Furthermore, Akt is dephosphorylated at
Thr308 (converting it into the inactive form) at reduced
levels of intracellular reactive oxygen species (ROS) [23],
making SOD an attractive therapeutic agent for sensitiz-
ing cancer cells to TRAIL-induced apoptosis. Because
TRAIL can be internalized via receptor-mediated endo-
cytosis [24], we hypothesized that iron superoxide dis-
mutase (FeSOD) could be internalized with sTRAIL to
reduce the level of intracellular O2
-. Here we cloned and
coexpressed sTRAIL (114 to 281 aa) and FeSOD, as well
as a fusion protein containing both, to determine
whether the resultant fused protein possessed dual activ-
ity and could exert a synergistic effect on cancer cells.
We observed sTRAIL:FeSOD to engage the TRAIL
receptors (TRAIL-R1 and TRAIL-R2), resulting in inter-
nalization of the receptor and ligand. Once inside the
cell, sTRAIL:FeSOD scavenged intracellular O2
-,w h i c h
then influenced the TRAIL-induced apoptosis pathway.
Results
Production of sTRAIL:FeSOD
After addition of isopropyl-b-D-thiogalactoside (IPTG),
the expected proteins sTRAIL (21.6 kDa), enzymatic activ-
ity deficient form of fused protein (sTRAIL:mFeSOD)
(42.6 kDa) and sTRAIL:FeSOD (42.6 kDa) were recovered
as demonstrated by Western blot analysis with an anti-
TRAIL antibody (Figure 1A). The sTRAIL:FeSOD and
sTRAIL:mFeSOD proteins were expressed in inclusion
bodies and required refolding to regain activity. The tri-
meric structure is the basis of sTRAIL-induced apoptotic
function. To determine whether the FeSOD domain
changes the oligomerization state of sTRAIL, renatured
sTRAIL:FeSOD was collected and run over a Sephadex
G-100 column (GE Healthcare, Fairfield, Connecticut,
USA). The renatured proteins were identified to be homo-
geneous (data not shown). Renatured sTRAIL:FeSOD was
further shown to be trimeric by performing native polya-
crylamide gel electrophoresis (PAGE) Western blot analy-
sis (Figure 1B). SOD activity assays indicated that the
antioxidant activity of renatured sTRAIL:FeSOD was 2,300
U/mg, whereas that of natural Nostoc commune FeSOD
was 3,500 U/mg. sTRAIL:mFeSOD show no antioxidant
activity. The induction of apoptosis in TRAIL-sensitive
LO2 cells indicated sTRAIL activity. To exclude the effects
of FeSOD, the LO2 cells were incubated in RPMI 1640
medium with 0.25 M sucrose, a condition in which inter-
nalization was inhibited (Figure 2D) [25]. The sTRAIL
activity assay results are shown in Figure 1C. LO2 cells
treated in hyperosmotic medium with 500 ng/ml sTRAIL
showed a 57.2% cell death rate, whereas sTRAIL:FeSOD
and sTRAIL:mFeSOD treated with 1,000 ng/ml sTRAIL
had cell death rates of 48.3% and 41.5%, respectively.
Sensitization of K562 and HL-60 cell lines to sTRAIL:
FeSOD
As described above, many tumor cells are resistant to
TRAIL because of phosphorylated Akt (p-Akt) upregula-
tion. Recently, we discovered that FeSOD can downre-
gulate the levels of p-Akt [19], and therefore we were
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cooperate with TRAIL to enhance the killing of tumor
cells. To address this question, the TRAIL-resistant ery-
throleukemia (K562) cells and human promyelocytic
leukemia (HL-60) cells [26] were used to detect the anti-
tumor ability of sTRAIL:FeSOD. Compared with
sTRAIL:mFeSOD or sTRAIL, K562 and HL-60 cells
demonstrated significantly less viability after treatment
with sTRAIL:FeSOD, and their antitumor activity
increased significantly in a sTRAIL:FeSOD dose-
dependent manner. The decrease in cell viability was
ascribed to apoptosis as demonstrated by anti-annexin
V antibody and propidium iodide (PI) staining (Figures
1D and 1E), strongly suggesting that sTRAIL and
FeSOD synergistically induced apoptosis in the TRAIL-
resistant K562 and HL-60 tumor cells. In contrast to the
effect in these two cell lines, sTRAIL:FeSOD did not
sensitize freshly isolated peripheral blood T cells to
death induced by apoptosis (Figure 1F). As TRAIL
induces apoptosis in normal human hepatocytes, the
LO2 cells were also treated as a control group. Interest-
ingly, the LO2 cells, which are extremely sensitive to
TRAIL-induced apoptosis [5], were less sensitive to
sTRAIL:FeSOD (Figure 1G).
Rapid internalization of sTRAIL:FeSOD
The ability of sTRAIL:FeSOD to enter the cell is the basis
for the synergistic effect of sTRAIL and FeSOD. After
incubation with labeled sTRAIL:FeSOD for 5 minutes,
the K562 cells began to show fluorescence (Figure 2A).
Internalization increased at 15 minutes (Figure 2B) with
marked fluorescence and fluorescence was even stronger
by 30 minutes (Figure 2C). As the cell surface-associated
ligand was stripped by acid washing, the internal fluores-
cence of the cells could be determined. Uptake of
sTRAIL:FeSOD was completely blocked by hypertonic
medium in LO2 cells (Figure 2D). Quantitative data
detected by flow cytometry indicated internalization rates
for FeSOD, sTRAIL:mFeSOD and sTRAIL:FeSOD of
1.38%, 82.56% and 85.43%, respectively (Figures 2E to
2H). Internalization of sTRAIL:FeSOD in HL-60 and
LO2 cells, which underwent the same treatment pro-
cesses as did the K562 cells, were confirmed by LSCM.
However, normal T cells showed low fluorescence
Figure 1 Western blot analysis of soluble forms of recombinant tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL),
enzymatic activity deficient form of fused protein (sTRAIL:mFeSOD) and sTRAIL:iron superoxide dismutase (FeSOD) expression and
sTRAIL:FeSOD-induced cell death. (A) After isopropyl-b-D-thiogalactoside induction, the expressed sTRAIL, sTRAIL:mFeSOD or sTRAIL:FeSOD
was subjected to Western blot analysis with anti-TRAIL antibody. Lanes 1 to 5 are sTRAIL control (Peprotech, Rocky Hill, New Jersey, USA) and
extracts of BL-21 transformed with pET28, pET28-sTRAIL, pET28-sTRAIL:mFeSOD and pET28-sTRAIL:FeSOD, respectively. (B) Samples were prepared
and electrophoresed using native polyacrylamide gel electrophoresis (PAGE) under nondenaturing conditions followed by electrotransfer and
immunoblotting with TRAIL antibody. Lanes 1 to 3 are sTRAIL control (purchased from Peprotech), sTRAIL:FeSOD (before renaturation) and
sTRAIL:FeSOD (renatured), respectively. (C) Six-well plates were seeded with LO2 cells and allowed to adhere before replacement with RPMI 1640
medium with hyperosmotic sucrose (0.25 M) containing sTRAIL (500 ng/ml), sTRAIL:FeSOD (1,000 ng/ml) or sTRAIL:mFeSOD (1,000 ng/ml). After
treatment for 8 hours, cell death was quantified by flow cytometry. (D) through (G) Cells were grown in six-well plates to 60% confluence, and
the indicated proteins were added at the indicated concentrations. After treatment for 8 hours, cells were stained with fluorescein isothiocyanate
anti-annexin V antibody and propidium iodide and then examined using flow cytometric analysis. For each sample, 10,000 events were acquired.
Results are expressed as the mean fluorescence intensity. Each bar represents the mean ± SE obtained from three independent experiments.
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dismutase (sTRAIL:FeSOD) is rapid and is inhibited by hyperosmotic sucrose. (A) through (C) Suspended erythroleukemia (K562) cells were
treated with fluorescein isothiocyanate (FITC)-labeled sTRAIL:FeSOD (green) in RPMI 1640 medium without fetal calf serum for (A) 5 minutes, (B)
15 minutes or (C) 30 minutes. After acid washes, cells were visualized with laser scanning confocal microscopy (LSCM). The LSCM parameters
were set to an excitation wavelength of 488 nm, an emission wavelength of 500 to 550 nm and pinhole of 202 μm. (D) LO2 cells were
preincubated for 30 minutes in the presence of 0.25 M sucrose at 37°C before incubation in the presence of FITC-labeled sTRAIL:FeSOD (green)
for an additional 30 minutes. After being washed extensively in ice-cold phosphate-buffered saline (PBS), cells were counterstained with Hoechst
33342 (blue) and analyzed by LSCM. The white bar represents 5 μm. The LSCM parameters for FITC were set to an excitation wavelength of 488
nm, an emission wavelength of 500 to 550 nm and pinhole of 215 μm. For Hoechst 33342, the parameters were set to an excitation wavelength
of 350 nm, an emission wavelength of 460 to 480 nm and pinhole of 215 μm. (E-H) After K562 cells were treated with PBS, FITC-labeled FeSOD,
sTRAIL:FeSOD or sTRAIL:mFeSOD for 30 minutes, the internalization rate was quantified by flow cytometry.
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of TRAIL death receptors [27] (data not shown).
sTRAIL:FeSOD neutralizes free radical O2
- and
reduces ROS
SOD is a potent antiradical enzyme, and Akt activity can
be downregulated under low levels of ROS. To investi-
gate the intracellular antioxidant activity of sTRAIL:
FeSOD, we measured ROS levels using the oxidation-
sensitive fluorescent dyes dichlorodihydrofluorescein
diacetate (DCFDA) (for total ROS) and dihydroethidium
(DHE) (for O2
-). The O2
- and ROS levels in leukemia
cells decreased significantly after pretreatment with
sTRAIL:FeSOD (Figures 3A and 3B). However, in con-
trast to the phosphate-buffered saline (PBS) control,
pretreatment with sTRAIL:mFeSOD or FeSOD did not
cause a significant difference in these roles, ruling out a
role for sTRAIL in O2
- quenching and confirming the
low permeability of SOD.
SOD is well known to induce H2O2 production during
O2
- scavenging, and therefore we monitored the changes
in H2O2,O 2
-, ROS and glutathione (GSH) levels after
treating the cells with sTRAIL:FeSOD. As shown in
Figures 3C to 3F, H2O2 levels increased 1 or 2 hours
after administration of sTRAIL:FeSOD in K562 and
HL-60 cells in comparison with the levels in LO2 and
T cells. However, at 3 hours after treatment, we observed
that H2O2 levels had declined almost to normal levels.
As compared with sTRAIL:mFeSOD, sTRAIL:FeSOD
induced a notably more significant decrease in cellular
ROS and O2
- fluorescence intensities and a marked rise
in GSH levels in the K562 and HL-60 cells (Figures 3C to
3F). Figure 3G shows that the redox status in LO2 cells
changed, but not as strongly as they did in the cancer
cells or in the sTRAIL:mFeSOD-treated LO2 cells. As
shown in Figure 3H, normal T cells maintained a stable
redox status, which may explain why they did not
undergo sTRAIL:FeSOD-induced apoptosis. Figure 3I
shows that sTRAIL:mFeSOD-induced apoptosis in LO2
cells was accompanied by a rapid increase in ROS levels.
The graph also shows that 3 hours after sTRAIL:FeSOD
treatment in the two leukemia cell lines, ROS levels did
not increase along with the decrease in H2O2, suggesting
that H2O2 was broken down by the cellular antioxidant
defenses rather than giving rise to highly reactive hydro-
xyl radicals [28].
sTRAIL:FeSOD-induced apoptosis does not involve the
mitochondrial apoptotic pathway
One parameter that is altered by the ROS production is
mitochondrial membrane potential (ΔΨm), and cancer
cells display a strong resistance to chemotherapeutic
agents, which is probably due to their efficacious protec-
tion against the mitochondrial apoptotic pathway. To
examine the role of the mitochondrial apoptotic path-
way in K562 and HL-60 cells undergoing sTRAIL:
FeSOD-induced apoptosis, ΔΨm was analyzed by flow
cytometry. Figures 4A and 4B show an increase in rho-
damine123 (Rh123) and JC-1 fluorescence intensity in
all four cell lines except the normal T cells after treat-
ment with sTRAIL:FeSOD, indicating that the mito-
chondria remained polarized during apoptosis in K562
and HL-60 cells. The lack of a significant change in
Rh123 and JC-1 fluorescence intensity in normal T cells
m a yb er e l a t e dt ot h es t a b l er e d o xs t a t u s( F i g u r e s3 H
and 3J). The data shown in Figure 4C imply that low
levels of ROS and high levels of GSH maintain the
ΔΨm and that hyperpolarized mitochondria can reduce
ROS to a lower level. Cytochrome c release did
not occur during sTRAIL:FeSOD-induced apoptosis
(Figure 4D). LO2 are type II cells, and sTRAIL was able
to apoptose the LO2 cells in the presence of mitochon-
drial dysfunction (Figures 1G, 4A and 4B).
sTRAIL:FeSOD-induced death is dependent on caspase-8
A common feature of cell death through apoptosis is
the activation of caspases. The inhibition of caspase-8
expression effectively protected K562 and HL-60 cells
from sTRAIL:FeSOD-induced apoptosis (Figures 5A
and 5B). This result indicates that sTRAIL:FeSOD-
induced apoptosis is dependent on caspase activation
and that caspase-8 acts as the major initiator caspase
in sTRAIL:FeSOD-induced apoptosis in these cells
(Figures 5C to 5E). In contrast, decreased expression
of caspase-9 did not significantly suppress sTRAIL:
FeSOD-induced apoptosis in the leukemia cells
(Figures 5A and 5B), suggesting the apoptosis to be
caspase-9-independent. Changes in caspase-8 and cas-
pase-3 activity in the two leukemia cell lines were
markedly greater than those in the LO2 and T cells
(Figure 5C), mirroring the different fate of the four cell
lines after treatment with sTRAIL:FeSOD. In contrast
to the control, there was no obvious change in cas-
pase-9 activity in any of the four cell types.
The internalization of FeSOD is indispensable for sTRAIL:
FeSOD-induced apoptosis
First, we examined the expression of TRAIL receptors
and whether treatment with sTRAIL:FeSOD led to ele-
vated surface expression of DR4 and DR5. No major
differences were found in the expression of either DR4
or DR5 after 6 hours of sTRAIL:FeSOD treatment
(Figure 5F). To determine which receptor is involved in
the death induced by sTRAIL:FeSOD and to discern
whether the uptake of sTRAIL:FeSOD is receptor-
dependent, we then performed an experiment in which
we added blocking antibodies against DR5 and/or DR4
for 1.5 hours prior to sTRAIL:FeSOD exposure [29].
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Page 5 of 16Figure 3 Effects of soluble forms of recombinant tumor necrosis factor-related apoptosis-inducing ligand:iron superoxide dismutase
(sTRAIL:FeSOD) on intracellular H2O2, glutathione (GSH), superoxide radical (O2
-) and reactive oxygen species (ROS) levels. (A) and (B)
After treatment with sTRAIL:FeSOD (1,000 ng/ml), sTRAIL:mFeSOD (1,000 ng/ml) or FeSOD (500 ng/ml) for 3 hours, dihydroethidium (DHE) or
dichlorodihydrofluorescein diacetate (DCFDA) was added for detection. (C) through (J) After cells were treated with sTRAIL:FeSOD (1,000 ng/ml)
or sTRAIL:mFeSOD (1,000 ng/ml) for 0, 1, 2, 3, 4, 5 or 6 hours, intracellular H2O2, GSH, O2
- and ROS were measured by DHR123, NDA, DHE and
DCFDA, respectively. The fluorescence was measured by flow cytometry. For each sample, 10,000 events were acquired. Results are expressed as
the mean fluorescence intensity. Each bar represents the mean ± SE obtained from three independent experiments (*P < 0.05 vs. untreated
control).
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body partially protected the K562 and HL-60 cells from
cell death, whereas the antibody against DR5 had a
more pronounced protective effect on sTRAIL:FeSOD-
induced apoptosis than did the antibody against DR4.
No significant apoptosis was noted when blocking with
both anti-TRAIL receptor antibodies. These results indi-
cate that the sTRAIL:FeSOD-induced death signaling in
the two cell lines depends on DR5 and DR4. After
blocking with antibodies against DR5 and/or DR4, the
Figure 4 Effects of soluble forms of recombinant tumor necrosis factor-related apoptosis-inducing ligand:iron superoxide dismutase
(sTRAIL:FeSOD) on mitochondrial membrane potential (ΔΨm). (A) and (B) ΔΨm was measured with (A) rhodamine123 (Rh123) and (B) JC-
1. After treatment with sTRAIL:FeSOD (1,000 ng/ml), sTRAIL:mFeSOD (1,000 ng/ml) or FeSOD (500 ng/ml) for 6 hours, cells were incubated for 30
minutes at 37°C with 10 μM Rh123 or 1 μg/ml JC-1 in phosphate-buffered saline and then subjected to flow cytometric analysis. For each
sample, 10,000 events were acquired. Results are expressed as a ratio of the relative fluorescence intensity. Each bar represents the mean ± SE
obtained from three independent experiments (*P < 0.05 vs. untreated control). (C) Kinetic relationship of redox state (indicated as the
glutathione (GSH)/reactive oxygen species (ROS) ratio) and ΔΨm after treatment with sTRAIL:FeSOD. Human promyelocytic leukemia (HL-60) cells
or erythroleukemia (K562) cells were treated with sTRAIL:FeSOD (1,000 ng/ml) for 0, 1, 2, 3, 4, 5 or 6 hours and then subjected to ROS, GSH and
ΔΨm (JC-1) analysis as described above. (D) Analysis of mitochondrial cytochrome c release. Cells were also incubated for 6 hours with or
without sTRAIL:FeSOD (1,000 ng/ml). Cytosolic (Cyto) and mitochondrial (Mito) fractions were prepared from these cells and assessed by Western
blot analysis.
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Page 7 of 16Figure 5 Involvement of caspase-8 and the role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor and H2O2
in soluble forms of recombinant TRAIL:iron superoxide dismutase (sTRAIL:FeSOD)-induced apoptosis. (A) and (B) Involvement of
caspase-8 in sTRAIL:FeSOD-induced apoptosis. Caspase-8 or caspase-9 small interfering RNA was transfected into the indicated cells for 24 hours.
After determining the inhibition of caspase-8 or caspase-9 expression (A), cells were treated with sTRAIL:FeSOD (1,000 ng/ml) for 8 hours, and
cell apoptosis was assayed by flow cytometry (B). (C) Cells were treated with sTRAIL:FeSOD (1,000 ng/ml) for 6 hours. Cell lysates were tested for
protease activity by the addition of caspase-specific peptides. Cleavage of the peptide by the caspase releases a chromophore, which was
quantified using a fluorometer at 505 nm. (D) and (E) Cells were treated with sTRAIL:FeSOD at the indicated concentrations for 6 hours. Cell
lysates were subjected to Western blot analysis using cleaved caspase-8, caspase-9 or caspase-3 antibody. (F) The DR5 and DR4 from untreated
cells or cells treated with sTRAIL:FeSOD (for 6 hours) were quantified by Western blot analysis. (G) Cells were incubated with DR5 antibody and/
or DR4 antibody for 1.5 hours prior to exposure to sTRAIL:FeSOD (1,000 ng/ml). (H) After cells were pretreated with sTRAIL:FeSOD for 0, 1, 2, 3 or
4 hours, 10 mM N-acetylcysteine (NAC) was added to the medium, and apoptosis was detected when cells had been treated with sTRAIL:FeSOD
for 8 hours. (I) through (K) After pretreatment with 10 mM NAC for 24 hours, cells were incubated in fresh medium with 1,000 ng/ml sTRAIL:
FeSOD or sTRAIL:mFeSOD for 8 hours. Apoptosis was determined by staining cells with anti-annexin V antibody and propidium iodide. H2O2 and
reactive oxygen species levels were also detected after NAC-pretreated cells were treated with sTRAIL:FeSOD for 0, 2, 4 and 6 hours as described
above. The untreated cells served as control. Data represent the mean ± SD of three independent experiments (*P < 0.05 vs. untreated control).
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tosis results, showing death receptor dependence. There
was minimal uptake of sTRAIL:FeSOD when pretreated
with both anti-TRAIL receptor antibodies (data not
shown), demonstrating the endocytosis to be receptor-
mediated.
To provide evidence for the synergistic effect of
sTRAIL and FeSOD, K562 and HL-60 cells were treated
in hypertonic medium containing sTRAIL:FeSOD, con-
ditions under which internalization of FeSOD was inhib-
ited. Figure 5G shows that the sTRAIL:FeSOD-induced
apoptosis drastically declined in the hypertonic medium,
demonstrating FeSOD to be indispensable for sTRAIL:
FeSOD-induced apoptosis. The confirmed internaliza-
tion of sTRAIL:mFeSOD into K562 and HL-60 cells
(Figure 2G) and the indistinguishable cell death in the
two cell lines after treatment with sTRAIL:mFeSOD
(Figures 1D and 1E) further prove the necessity for
FeSOD to be internalized to allow for sTRAIL:FeSOD-
induced apoptosis.
A brief accumulation of H2O2 is involved in sTRAIL:
FeSOD-induced apoptosis
We observed that the elevated H2O2 levels lasted about
2 hours in K562 and HL-60 cells after treatment with
sTRAIL:FeSOD (Figures 3C and 3D). H2O2 has been
reported to have a direct effect on caspase-8 activation,
and therefore we investigated whether H2O2 was
involved in sTRAIL:FeSOD-induced apoptosis. To that
end, cells were treated with sTRAIL:FeSOD in the pre-
sence or absence of N-acetylcysteine (NAC) [30]. After
pretreatment with sTRAIL:FeSOD for 0, 1 or 2 hours,
the addition of NAC partially reduced sTRAIL:FeSOD-
induced apoptosis (Figure 5H). When the cells were pre-
treated with sTRAIL:FeSOD for more than 3 hours,
NAC did not show any significant inhibitory effect on
sTRAIL:FeSOD-induced cell death. Thus, the results
indicate that the production of H2O2 during O2
- scaven-
ging contributed to sTRAIL:FeSOD-induced apoptosis
and that caspase-8 activation by H2O2 occur within the
first 2 hours after sTRAIL:FeSOD treatment. To further
assess the role of H2O2 produced during O2
- scavenging
in sTRAIL:FeSOD-induced apoptosis, we examined the
apoptosis induced by sTRAIL:FeSOD after eliminating
intracellular O2
- by pretreating HL-60 and K562 cells
with NAC for 24 hours (Figures 5I to 5K). Because of
the prescavenging of O2
-, there was little substrate for
FeSOD, which caused the H2O2 to remain at a very low
level during the treatment with sTRAIL:FeSOD. Figure 5I
shows that cell death was reduced. These data suggest
that H2O2 plays an important role in sTRAIL:FeSOD-
induced apoptosis.
Downregulation of p-Akt and c-FLIPL promotes TRAIL-
induced apoptosis in HL-60 and K562 cells
It is known that p-Akt can be activated by ROS and that
elevated Akt activity protects cells against TRAIL-
induced apoptosis. Figure 5H shows that decreased
H2O2 levels did not entirely inhibit sTRAIL:FeSOD-
induced apoptosis. Thus, we postulated that Akt may
also be involved in sTRAIL:FeSOD-induced apoptosis in
K562 and HL-60 cells. p-Akt was rapidly dephosphory-
lated within 30 minutes of adding sTRAIL:FeSOD with-
o u tc h a n g i n gt h eA k tp r o t e i nl e v e l ,a n ds T R A I L : F e S O D
treatment markedly depressed the c-FLIPL level in the
two leukemia cell lines (Figures 6A and 6B). c-FLIPS
was not detected in the HL-60 cells (Figure 6A). c-FLIPS
was detected in K562 cells, but did not show any change
in expression levels after sTRAIL:FeSOD addition (Fig-
ure 6B). Therefore, we hypothesize that c-FLIPL is
involved in sTRAIL:FeSOD-induced apoptosis. sTRAIL:
FeSOD-induced apoptosis in K562 and HL-60 cells was
partially inhibited by c-FLIPL overexpression (Figures 7A
to 7C), demonstrating that the p-Akt/c-FLIPL signaling
pathway is also involved in sTRAIL:FeSOD-induced apop-
tosis. The effect of sTRAIL:FeSOD on the downregulation
of c-FLIPL was also determined in cells in which total cas-
pases were blocked (Figure 6E), further proving that c-
FLIPL levels were modulated by Akt. Bcl-2 family proteins
are important pro- and antiapoptotic proteins in the cells,
but we were unable to detect any changes in Bcl-2, Bcl-XL
and Bax levels or Bid cleavage after 6 hours of sTRAIL:
FeSOD treatment.
Low levels of H2O2 protect LO2 cells from sTRAIL:FeSOD-
induced apoptosis
The downregulation of p-Akt and c-FLIPL was also
observed in LO2 cells (Figure 6C), but not in normal T
cells (data not shown). It was not immediately apparent
why TRAIL sensitivity did not occur in LO2 cells. LO2
cells are type II, and TRAIL-induced apoptosis can be
blocked by caspase-9 inhibition in these cells (Figure 7D).
The results presented in Figure 3I and Figures 4A and 4B
also suggest that sTRAIL-induced apoptosis in LO2 cells
was dependent on mitochondria. Caspase-9 activity was
low, and mitochondria remained polarized after treat-
ment with sTRAIL:FeSOD, which inhibits the mitochon-
drial apoptotic pathway. Therefore, we hypothesized that
the low levels of H2O2 prevented sTRAIL:FeSOD from
converting LO2 into type I cells, which are characterized
by high caspase-8 activity. To test this hypothesis, RNA
interference transfection was performed to depress cata-
lase expression in the LO2 cells, and the H2O2 levels
were found to be much higher than those in the control
group after treatment with sTRAIL:FeSOD (Figure 7E).
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sTRAIL:FeSOD (Figures 7F and 7G) in the catalase-defi-
cient LO2 cells. On the basis of these experimental data,
LO2 cells are not converted into type I cells after treat-
ment with sTRAIL:FeSOD. On the contrary, sTRAIL:
FeSOD not only depressed caspase-9 activity but also
maintained caspase-8 activity below a critical threshold
because of the low H2O2 levels, rendering the LO2 cells
insensitive to sTRAIL:FeSOD-induced apoptosis. Thus,
without the accumulation of H2O2, downregulation of p-
Akt and c-FLIPL was insufficient to activate enough cas-
pase-8 to sensitize LO2 to TRAIL-induced apoptosis at a
low level of oxidative stress.
Discussion
Here we describe a novel therapeutic approach for treat-
ing cancer using the new cell-permeable fusion protein
sTRAIL:FeSOD. The effects of sTRAIL and sTRAIL:
FeSOD on apoptosis in LO2 cells in hyperosmotic med-
ium did not show significant differences, suggesting that
the FeSOD domain does not change the oligomerization
state of sTRAIL (Figures 1B and 1C). When engaging
the TRAIL receptors (TRAIL-R1 and TRAIL-R2), the
trimeric sTRAIL:FeSOD triggered the TRAIL-induced
apoptotic signaling pathway and simultaneously perme-
ated the cell membrane via the receptor-mediated endo-
cytic pathway. Movement throughout the cytoplasm
Figure 6 Effects of soluble forms of recombinant tumor necrosis factor-related apoptosis-inducing ligand:iron superoxide dismutase
(sTRAIL:FeSOD) on the levels of phosphorylated Akt and antiapoptotic proteins. (A) and (B) Dose response of Akt dephosphorylation and
cellular FLICE-inhibitory protein (c-FLIPL) downregulation by sTRAIL:FeSOD in human promyelocytic leukemia (HL-60) cells or erythroleukemia
(K562) cells. Before they were disrupted, cells expressing phosphorylated Akt (p-Akt), c-FLIPL and c-FLIPS were treated with sTRAIL:FeSOD for 30
minutes, 1 hour and 1 hour, respectively. Bcl-xl, Bcl-2, Bax and Bid levels were detected after treatment with sTRAIL:FeSOD for 6 hours. (C) After
treatment of LO2 cells with sTRAIL:FeSOD (500 μg/ml) or LY294002 (10 μM) for 4 hours, cell lysates were probed for p-Akt and c-FLIPL. (D)
Enhancement of TRAIL-induced cytotoxicity caused by LY294002 (10 μM) in LO2 cells. Cells were pretreated with LY294002 for 30 minutes and
then treated with sTRAIL:mFeSOD (1,000 ng/ml) or left untreated for 8 hours. Cell survival was determined by staining cells with anti-annexin V
and propidium iodide. (E) In the presence or absence of the specific inhibitor of total caspase 50 μM (Z-VAD-FMK, benzyloxycarbonyl-Val-Ala-Asp
(OMe) fluoromethylketone), cells were treated with 1,000 ng/ml sTRAIL:FeSOD for 1 hour, and then c-FLIPL levels were determined by Western
blot analysis.
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Page 10 of 16provided FeSOD with the opportunity to scavenge O2
-
originating from the mitochondria. Once sTRAIL:
FeSOD engaged the TRAIL receptors, TRAIL-induced
apoptosis signaling was triggered, seemingly prior to the
elimination of intracellular O2
-. However, in the current
study, the brief accumulation of H2O2 and the downre-
gulation of p-Akt occurred rapidly enough to enhance
the sensitivity of K562 and HL-60 cancer cells to
TRAIL-induced apoptosis. The internalization of
sTRAIL:FeSOD was rapid (Figure 2) and triggered
TRAIL-induced apoptosis signaling and the elimination
of intracellular O2
- to occur nearly simultaneously. In
addition, it has been suggested that Fas-associated pro-
tein with death domain and caspase-8 are not recruited
soon enough because of the long delay in death-
inducing signaling complex assembly in type II cells
[31]. Thus, FeSOD had sufficient time to scavenge intra-
cellular O2
- and then influence the course of TRAIL-
induced apoptosis.
The inhibition of H2O2 accumulation or the overex-
pression of c-FLIPL partially suppressed sTRAIL:FeSOD-
induced apoptosis, and thus we infer that H2O2 and
p-Akt affect caspase-8 activity via different pathways.
Constitutive phosphoinositide 3-kinase (PI3K)/Akt activ-
ity has been demonstrated to be one of the most effective
antiapoptotic survival pathways in TRAIL-resistant cells,
and therefore decreasing p-Akt levels is an important
mechanism of averting TRAIL resistance. Tumor cells
containing an activating somatic mutation in PI3K are
relatively resistant to TRAIL-induced apoptosis [32,33].
After treatment with sTRAIL:FeSOD, p-Akt was downre-
gulated in three cell lines (Figures 6A to 6C), depressing
c-FLIPL expression [20]. However, the LO2 cells
responded little to the fusion protein, in contrast to the
synergistic apoptosis in TRAIL-resistant K562 and HL-60
cells [26]. The downregulation of Akt activity by
LY294002 promoted TRAIL cytotoxicity in LO2 cells
(Figure 6D), implying that low oxidative stress induced
by FeSOD inhibited TRAIL-induced apoptosis in the
LO2 cells. The results of the present study suggest that
differences in caspase-8 activity determine the different
cellular effects of sTRAIL:FeSOD on the indicated cells
based on the interruption of the mitochondrial apoptotic
pathway (Figures 4A, B and 5B to 5E). ROS have been
reported to regulate caspase activation in TRAIL-
resistant human colon carcinoma cells [17]. Perez-Cruz
et al. [34] indicated that intracellular vitamin C can
quench some of these ROS, reducing caspase-8 activa-
tion, similar to what we observed in the LO2 cells. How-
ever, Fas et al. [10] found that wogonin sensitizes
resistant malignant cells to TRAIL by shifting levels of
the TRAIL-induced free radical O2
-, consistent with our
Figure 7 Cellular FLICE-inhibitory protein (c-FLIPL) is involved in soluble forms of recombinant tumor necrosis factor-related
apoptosis-inducing ligand:iron superoxide dismutase (sTRAIL:FeSOD)-induced apoptosis, and the lack of responsiveness to sTRAIL:
FeSOD in LO2 cells results from low levels of H2O2. (A) through (C) Effects of c-FLIPL overexpression on apoptosis and caspase-8 activities.
After determination of c-FLIPL overexpression (A), cells were treated with sTRAIL:FeSOD (1,000 ng/ml) or sTRAIL:mFeSOD (1,000 ng/ml), and
apoptosis (B) and caspase-8 activity (C) were subsequently assayed. (D) Caspase-9 small interfering RNA (siRNA) was transfected into LO2 cells
for 24 hours. After determining the inhibition of caspase-9 expression, cells were treated with sTRAIL:FeSOD (1,000 ng/ml) or sTRAIL:mFeSOD
(1,000 ng/ml) for 8 hours, and cell apoptosis was assayed by flow cytometry. (E) through (G) Effect of H2O2 burst on cell death and caspase-8
activity in LO2 cells. After catalase siRNA transfection for 24 hours, cells were treated with 1,000 ng/ml sTRAIL:FeSOD for 0, 1, 2 or 3 hours, and
then intracellular H2O2 was measured using dihydrorhodamine 123 (E). Cells were treated with sTRAIL:FeSOD (1,000 ng/ml) or sTRAIL:mFeSOD
(1,000 ng/ml), and apoptosis (F) and caspase-8 activity (G) were subsequently assayed. Data represent the mean ± SD of three independent
experiments (*P < 0.05 vs. untreated control).
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Page 11 of 16results demonstrating the sensitization of K562 and
HL-60 cells.
ROS levels have been found to be significantly higher in
cancer cells than in normal cells, and the activity of anti-
oxidant enzymes such as glutathione peroxidase, catalase
and SOD has been shown to be significantly lower in can-
cer patients than in controls [35]. The higher ROS levels
and lower antioxidant enzyme activities (Figures 3C to 3F)
make the transient burst of H2O2 possible in K562 and
HL-60 cells; however, because of the lower ROS levels and
vigorous antioxidant system, the brief accumulation of
H2O2 was not detected in LO2 cells (Figures 3G and 3I).
The brief accumulation of H2O2 during O2
- scavenging
was involved in the sTRAIL:FeSOD-induced apoptosis in
K562 and HL-60 cells (Figures 5H to 5K), possibly exert-
ing a direct effect on caspase-8 activation [36]. The low
H2O2 levels protected LO2 cells from sTRAIL:FeSOD-
induced apoptosis (Figures 7E to 7G). Normal T cells pro-
duced very little ROS, and therefore only a small shift in
redox state was seen, which may explain why sTRAIL:
FeSOD did not sensitize normal T cells to undergo apop-
tosis. Our studies reveal that sTRAIL:FeSOD reduces the
level of intracellular O2
-, with two results: the downregula-
tion of p-Akt arising from a low level of O2
- and the tran-
sitory accumulation of H2O2, both of which may increase
the amount of available active caspase-8 [37]. However, a
low level of O2
-, impairing caspase-8 activation [36], and
stable mitochondria may inhibit apoptosis. Thus, we infer
that the relative ratio of these opposing effects described
above determines the sensitivity of a cell to sTRAIL:
FeSOD and that this relative ratio may be associated with
the cell type and the level of O2
-. Without the accumula-
tion of H2O2, the available activated caspase-8 was insuffi-
cient (Figures 5C and 7E to 7G). At the same time,
caspase-9 activity was inhibited (Figures 4 and 5C), which
means that the mitochondrial apoptotic pathway was
interrupted. Thus, sTRAIL:FeSOD cannot sensitize LO2
cells to apoptosis when there is insufficient activated cas-
pase-8 to excite the downstream apoptotic pathway in the
absence of the intrinsic apoptotic pathway. The induction
of apoptosis in K562 and HL-60 cells implies that the net
result of intracellular O2
- scavenging by sTRAIL:FeSOD is
the presence of a critical amount of activated caspase-8.
Thus, in environments of low-level oxidative stress, the
cellular context may influence the relative ratio of the
opposing effects and subsequently determine whether this
low level of oxidative stress favors apoptosis or survival.
Because of the effective protection against the mito-
chondrial apoptotic pathway mediated by the increased
expression of Bcl-XL and the mutation of caspase-8,
K562 and HL-60 cells exhibit strong resistance to che-
motherapeutic agents [38,39]. However, after treatment
with sTRAIL:FeSOD, K562 and HL-60 cells undergoing
apoptosis retained their ΔΨm( F i g u r e4 ) ,a n dw ea l s o
failed to detect a difference in the expression level of
Bcl-2, Bax, Bid or Bcl-XL (Figures 6A and 6B) or a
change in the distribution of cytochrome c (Figure 4D).
The unchanged pattern of cytochrome c localization
may be associated with a decrease in ROS levels, leading
to mitochondrial stability. Depressed caspase-9 expres-
sion did not suppress apoptosis, demonstrating that
sTRAIL:FeSOD-induced apoptosis was independent of
the mitochondrial apoptotic pathway in K562 and HL-
60 cells (Figures 5A and 5B). Mohr et al. [40] indicated
that high levels of MnSOD protect colorectal cancer
cells from TRAIL-induced apoptosis by inhibition of
Smac/DIABLO release. However, this effect may be lim-
ited to type II cells, in which death receptor-mediated
apoptosis is dependent on mitochondria. In contrast, in
the present study, treatment with sTRAIL:FeSOD caused
K562 and HL-60 cells to convert to type I cells and to
apoptose independently of the intrinsic apoptotic path-
way, consistent with the effects of erythroid differentia-
tion [41]. Thus, mitochondrial hyperpolarization does
not delay apoptosis when a critical amount of caspase-8
has been activated, which may be the mechanism that
regulates type I cell apoptosis independently of the
mitochondrial signaling pathway [36].
Death receptors are expressed in liver tissue as well as
in isolated hepatocytes [5], and for this reason sTRAIL:
FeSOD was able to permeate the cell membrane and
reduce the oxidative stress in LO2 cells without causing
cytotoxicity. Maintaining the balance of opposing effects
is important when treating normal cells with sTRAIL:
FeSOD, because an appropriate ROS level is extremely
important for preserving vital cellular and biochemical
functions. Our future work will focus on the task of esti-
mating intracellular ROS production in an individual
cell to determine a treatment dose that maintains ROS
levels at an appropriate interval, killing cancer cells
without inducing normal cell death. In light of the dif-
ferent sensitivities of different cell types to ROS and the
hypersensitivity of tumor cells to decreased levels of
ROS relative to normal cells, the ability to control
TRAIL cytotoxicity through the regulation of intracellu-
lar ROS levels will be a breakthrough in the utilization
of TRAIL. Undoubtedly, sTRAIL:FeSOD is a good
potential therapeutic choice.
Conclusions
In conclusion, our research has shown that a cell-
permeable fusion protein, sTRAIL:FeSOD, selectively
sensitized K562 and HL-60 cancer cells to TRAIL-
induced apoptosis but did not sensitize normal human
hepatocytes (LO2 cells) or T cells. sTRAIL:FeSOD is a
potent antioxidant that produces H2O2 during intracel-
lular O2
- scavenging and downregulates p-Akt and
c-FLIPL. Thus, sTRAIL:FeSOD enhances TRAIL-induced
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Page 12 of 16apoptosis in leukemia cells and, at the same time, avoids
the negative effects of high levels of ROS. After treat-
ment with sTRAIL:FeSOD, the mitochondria were still
intact, and the TRAIL-resistant K562 and HL-60 cells
successfully converted into type I cells. In addition, the
downregulation of c-FLIPL was not sufficient to sensitize
LO2 to TRAIL-induced apoptosis without H2O2 accu-
mulation. These data suggest that sTRAIL:FeSOD can




The fluorescent probes DHE, Rh123 and the peroxide-
sensitive fluorophore DCFDA were purchased from
Molecular Probes (Eugene, Oregon, USA). The total
caspase inhibitor Z-VAD-FMK (benzyloxycarbonyl-Val-
Ala-Asp (OMe) fluoromethylketone) and the Annexin
V-FITC Apoptosis Detection Kit were obtained from
Merck (Darmstadt, Germany). Caspase-9, caspase-3 and
caspase-8 fluorometric assay kits were obtained from
BioVision (Palo Alto, California, USA). Rabbit p-Akt
(Thr308) antibody; mouse Akt antibody; rabbit c-FLIPS
and c-FLIPL antibodies; Bcl-XL, Bcl-2, Bax and Bid anti-
bodies; caspase-9, caspase-3 and caspase-8 antibodies;
and horseradish peroxidase (HRP)-conjugated goat anti-
rabbit antibody were purchased from Cell Signaling
Technology (Boston, Massachusetts, USA), along with
LY294002 (PI3K inhibitor). TRAIL, DR4 and DR5 anti-
bodies and donkey antimouse immunoglobulin G-HRP
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). All of the remaining reagents were
purchased from Sigma (Saint Louis, Missouri, USA).
Cell lines and culture conditions
The pUCm-T-TRAIL vector was kindly provided by Pro
Liu (Institute of Biochemistry and Cell Biology, Shanghai
Institute for Biological Science, Chinese Academy of
Science (Shanghai, China). Escherichia coli DH5a [supE4
ΔlacU169 (80lacZΔM15) hsdR17 recA1 endA1 gyrA96
thi-1 relA1], E. coli BL21 (DE3) (hsdS gal (lcIts857 ind1
Sam7 nin5 lacUV5-T7 gene 1)), pET-28a(+) vector,
pUCm-T vector and pET22-FeSOD vector were available
at our institute. E. coli DH5a and E. coli BL21 (DE3)
were maintained at 37°C in Luria-Bertani (LB) medium
supplemented with the appropriate antibiotics. K562,
HL-60 and LO2 cells were available in our laboratory and
cultured in a humidified 5% CO2 atmosphere at 37°C in
RPMI 1640 medium supplemented with 10% fetal calf
serum and antibiotics (penicillin and streptomycin).
Human peripheral T cells were prepared as described
previously [42]. T cells were activated with 1 μg/ml poly-
hydroxyalkanoate for 20 hours, washed three times and
then cultured for an additional 5 days in the presence of
25 U/ml interleukin 2. Transfections of K562, HL-60 and
LO2 cells were performed with the expression vectors
pcDNA3-c-FLIPL, caspase-8 and caspase-9 small interfer-
ing RNA (siRNA), catalase siRNA or control siRNA
(Santa Cruz Biotechnology) using the Attractene trans-
fection reagent (Qiagen, Hilden, Germany).
Production, purification and immunoblot analyses
of sTRAIL and sTRAIL:FeSOD
A DNA fragment encoding the extracellular domain of
human TRAIL (sTRAIL; 114 to 281 aa) was amplified
from the pUCm-T-TRAIL vector with the primers
sTRAIL-NcoI( 5 ’-CATGCCATGGTGAGAGAAAGA
GGTCCTCAGAGAGTAG-3’)a n ds T R A I L - SalI( 5 ’-
ACGCGTCGACTCCGCCTCCACCGCCAACTAAAA
AGGCC-3’) and directionally inserted into pET28a(+)
plasmid to form pET28-sTRAIL using the unique NcoI
and SalI restriction enzyme sites. The FeSOD fragment
was amplified from the pET22-FeSOD vector, polymerase
chain reaction-amplified with FeSOD-SalI( 5 ’-ACGCGTC-
GACTCATTTGTACAGCTCCCACTACCCT-3’)a n d
FeSOD-NotI( 5 ’-ATAAGAATGCGGCCGCAGCTTTGG
CCAAGTTTTC-3’) primers and cloned in frame with the
unique SalIa n dNotI restriction enzymes, yielding plasmid
pET28-sTRAIL:FeSOD. Nucleotide sequences of the insert
regions within these constructs were independently
verified by automated DNA sequencing.
E. coli BL-21 DE3 (pLys) were transformed with
pET28-sTRAIL and then induced in the presence of
0.8 mM IPTG in 1 liter of LB culture medium at 27°C
for 3 hours [43]. Bacterial pellets were then collected by
centrifugation at 5,000 rpm for 5 minutes and washed
twice with ice-cold PBS. Pellets were sonicated and
lysed in Triton X-100 lysis buffer (10 mM TrisHCl, pH
7.6, 150 mM NaCl, 10% glycerol, 1% Triton X-100,
0.1 mM dithiothreitol (DTT), 0.1 mM phenylmethane-
sulfonylfluoride) for 30 minutes on ice. The lysis super-
natant was then cleared by centrifugation and poured
onto a column with 5 ml of nickel-nitrilotriacetic acid
Superflow resin (Qiagen), and the packed resin was
washed with buffer consisting of imidazole gradient con-
centrations (0 to 500 mM). The sTRAIL:FeSOD fusion
protein was expressed at 37°C and lysed from pET28-
sTRAIL:FeSOD as described above. The achieved sedi-
mentation (sTRAIL:FeSOD fusion protein) was then dis-
solved in lysis buffer (10 mM Tris HCl, pH 7.6,
150 mM NaCl, 8 M urea) overnight. The lysate was pur-
ified as described above. After purification, the dena-
tured protein was renatured in buffer (10 mM Tris HCl,
pH 7.6, 150 mM NaCl, 0.5 M L-arginine, 0.5 mM GSH,
0.5 mM L-Glutathione oxidized, 10% glycerol, 10 μM
Fe
3+,1 0μMZ n
2+) consisting of a gradient of urea con-
centrations (0 to 8 M) at 10°C. The renatured proteins
were collected and flowed over a Sephadex G-100
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the amino acid sequence in the conserved region (69 to
84 aa, 120 to 132 aa and 162 to 169 aa) of FeSOD, we
also produced a mutant form of fused protein (sTRAIL:
mFeSOD) that was deficient in its enzymatic activity.
The expression of sTRAIL, sTRAIL:FeSOD and sTRAIL:
mFeSOD was assessed by Western blot analysis. The
TRAIL-induced apoptosis activity of sTRAIL, sTRAIL:
FeSOD and sTRAIL:mFeSOD was assayed by treating
the TRAIL-sensitive LO2 cells in hypertonic medium
containing sucrose (0.25 M), conditions that inhibited
the endocytosis of TRAIL, eliminating the effect of
FeSOD [25]. The SOD activity of purified sTRAIL:
FeSOD was determined using the xanthine/xanthine
oxidase system. sTRAIL:mFeSOD was used as control to
analyze the cellular effects of sTRAIL:FeSOD.
Apoptosis assay
To identify early apoptotic changes, cells were seeded in
six-well plates (5 × 10
5 cells/well) and incubated for
8h o u r si nt h ep r e s e n c eo fF e S O D ,s T R A I L ,s T R A I L :
FeSOD or sTRAIL:mFeSOD. Cells were collected at
1,000 rpm for 5 minutes at 4°C. After being washed, the
cells were then stained with fluorescein isothiocyanate
(FITC)-conjugated anti-annexin V antibody and PI, fol-
lowed by flow cytometric analysis (Becton Dickinson,
Franklin Lakes, New Jersey, USA). The results are pre-
sented as the percentage of apoptosis. For each sample,
10,000 events were acquired in each group. Experiments
were performed three separate times for each cell line.
Preparation of FITC-labeled sTRAIL:FeSOD conjugate
By labeling with FITC, we could trace the permeation
process of sTRAIL:FeSOD through the cell membrane.
sTRAIL:FeSOD (10 mg) was dissolved in 5 ml of
500 mM carbonate buffer (pH 8.5) without sodium
azide. Ten milligrams of FITC were dissolved in 1 ml of
anhydrous dimethyl sulfoxide immediately before use,
and then 50 μl of FITC were added to the dissolved
sample. The tube was wrapped in foil and then incu-
bated and rotated at room temperature for 2 hours. The
labeled sTRAIL:FeSOD was desalted with a Sephadex
G-25 column to remove unreacted FITC. The fluores-
cence intensity of sample was measured by using a
fluorescence spectrophotometer. FeSOD and sTRAIL:
mFeSOD were treated as described above. No difference
was observed in the efficiency of FITC-labeled sTRAIL:
FeSOD compared with unlabeled protein in terms of
inducing apoptosis in LO2 cells (data not shown).
Determination of sTRAIL:FeSOD internalization by
confocal microscopy and flow cytometry
Prepared K562 cells were washed extensively with PBS
and incubated in RPMI 1640 medium containing 5 μg/
ml FITC-conjugated sTRAIL:FeSOD for 5, 15 or
30 minutes at 37°C. After internalization, following
three washes with PBS to remove unbound protein and
an acid wash (0.2 M NaCl, 0.2 M acetic acid) to strip
the surface-associated ligand, intracellular FITC was
observed by LSCM (LSM510; Carl Zeiss, Jene,
Germany), and quantitative data were analyzed by using
flow cytometry. LO2 cells were incubated in RPMI 1640
medium containing hyperosmotic sucrose (0.25 M) [44]
and 5 μg/ml FITC-conjugated sTRAIL:FeSOD and then
counterstained with the DNA dye Hoechst 33342
(Sigma).
Cellular oxidative stress assay by flow cytometry
After incubation with 1000 ng/ml sTRAIL:FeSOD in
fresh culture medium for the indicated amount of time,
cells were washed and incubated with 20 μMd i h y d r o r -
hodamine 123 (DHR123) (for H2O2), 50 μM2 , 3 -
Naphthalenedicarboxaldehyde (NDA) (for GSH), 20 μM
DHE (for O2
-)o r5μM DCFDA (for total ROS) at 37°C
for 30 minutes. The cells were then washed three times
with probe-free phosphate buffer. The fluorescence
intensity was measured by flow cytometry.
Measurement of mitochondrial membrane potential
Cells were precultured in a 24-well plate at a concentra-
tion of 0.5 × 10
6 cells/well. Subsequently, cells were
treated with 1,000 ng/ml sTRAIL:FeSOD, 500 ng/ml
rTRAIL or 500 ng/ml FeSOD for 6 hours or were left
untreated as controls. After treatment with sTRAIL:
FeSOD, cells were harvested and washed with pre-
warmed PBS. The cells were then incubated with 10 μM
Rh123 or 1 μg/ml JC-1 at 37°C for 30 minutes, washed
and subsequently analyzed by flow cytometry.
Caspase activity assay
Prepared cells (1 × 10
6/ml) were treated for 6 hours
with 1,000 ng/ml sTRAIL:FeSOD, 500 ng/ml rTRAIL or
500 ng/ml FeSOD and then lysed in ice-cold lysis buffer
(Biovision) for 10 minutes. After centrifugation for
10 minutes at 15,000 × g, cell lysates were tested for pro-
tease activity by the addition of reaction buffer (containing
10 mM DTT) and caspase-specific peptides conjugated to
the fluorescence AFC (7-amino-4-trifluoromethyl cou-
marin). Cleavage of the peptide by caspase releases the
chromophore, which was quantified using a fluorometer at
505 nm.
Western blot analysis
Treated cells were collected, washed in PBS and then
lysed with lysis buffer on ice. Approximately 20 μgo f
lysed protein were separated by sodium dodecyl sulfate-
PAGE and transferred to a nitrocellulose blotting mem-
brane, blocked for 1.5 hours in blocking buffer (5%
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Tris-buffered saline (TBST)). After three washes in
TBST, membranes were probed with the indicated anti-
bodies in blocking buffer overnight. After three washing
steps in TBST, the blots were subjected to appropriate
secondary antibodies for 1.5 hours in blocking buffer.
After two washes in TBST for 30 minutes, proteins
were visualized by chemiluminescence detection.
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